Avkare LLC

Avkare LLC, a pharmaceutical and medical supply distributor based in Pulaski, Tennessee, operates as a prime contractor supplying generic medications and medical equipment to federal healthcare agencies through delivery orders and indefinite delivery contracts, competing on an unrestricted, full-and-open basis with no small business set-asides. The company is a for-profit limited liability partnership registered in SAM.gov since 2007 and operates across multiple NAICS categories, primarily Surgical Appliance and Supplies Manufacturing (3,897 awards), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (1,351 awards), and Pharmaceutical Preparation Manufacturing (199 awards).

Avkare's federal footprint is overwhelmingly transactional. The vendor carries 6,879 total prime awards with $8.1 billion in combined potential value, but only $54.6 million (1% of potential value) has been obligated to date. The award portfolio spans nearly two decades of activity, with a sharp acceleration beginning in 2024—19 awards in 2022 and 2023 combined, rising to 115 in 2024 and 121 in 2025, with 103 awarded as of August 2026. The vast majority of this volume consists of small delivery orders under existing indefinite delivery contracts; individual orders frequently carry ceiling values under one thousand dollars for specific pharmaceutical products such as sulfamethoxazole-trimethoprim DS tablets ($147–$2,065), naloxone HCL nasal spray ($23–$435), cephalexin capsules ($50–$787), and venlafaxine HCL ER ($4–$48).

Customer concentration is extreme and fragmented by healthcare system. The Defense Logistics Agency Troop Support Medical accounts for 1,958 awards (29% of the total volume) valued at $1.03 billion in potential value, dominated by Medical Equipment and Supplies delivery orders (3,672 task orders, $218.4 million combined). The Department of Veterans Affairs dominates the dollar side: Veterans Health Administration Veterans Integrated Service Network 12 anchors $3.44 billion in potential value across 251 awards, while the VA National Acquisition Center carries $757 million across 55 larger IDC awards. The VA's remaining regional VISNs (Veterans Integrated Service Networks 7, 17, 22, and 2) collectively account for approximately 2,196 awards but only modest dollar totals. This split reflects Avkare's dual posture: high-volume, low-value delivery orders flowing through DLA's Medical Supply Chain and the VA's regional health systems on the one hand, and larger single-award indefinite delivery contracts anchored with the VA National Acquisition Center and DLA on the other.

Avkare holds a substantial portfolio of single-award indefinite delivery contracts, primarily with the Department of Veterans Affairs National Acquisition Center and the Defense Logistics Agency Medical Supply Chain. Recent IDC awards include Metformin Hydrochloride 24-hour sustained-release tablets ($90.7 million ceiling, awarded December 2025, base through December 2026 with four one-year options); Telmisartan tablets in three strengths ($64.6 million ceiling, December 2025–December 2030); Potassium Chloride Extended Release tablets ($39.51 million ceiling, October 2025–October 2030); and Montelukast Sodium chewable tablets ($2.03 million ceiling, August 2026–August 2027 base plus four one-year options). Additional contracts cover Mycophenolate Mofetil capsules and tablets ($24.9 million, June 2025 base), Abiraterone Acetate 250 mg tablets ($20.31 million, June 2025 base with Option Year One exercised), Aspirin/Dipyridamole sustained-action capsules ($9.01 million, May 2025 base with Option Year One exercised), Emtricitabine/Tenofovir Disoproxil Fumarate tablets ($9.98 million, October 2025 base), Metaxalone 800 mg tablets ($1.83 million, June 2026–June 2031), Anastrozole 1 mg tablets ($11.9 million, September 2025–September 2030), and Tenofovir Disoproxil Fumarate 300 mg tablets ($1.24 million with Option Year Two exercised). These IDCs serve multiple federal healthcare beneficiaries—the Department of Defense, Department of Veterans Affairs, Bureau of Prisons, Indian Health Service, and Federal Health Care Center—through established pharmaceutical prime vendor programs. All contracts are unrestricted, fully competitive procurements without set-asides; Avkare competes on demonstrated capability and pricing alone.

The vendor's representative delivery-order work includes hundreds of pharmaceutical procurement orders issued by the Defense Logistics Agency Medical Supply Chain between January and April 2026, each valued from single digits to several thousand dollars. A sample: Sulfamethoxazole-Trimethoprim DS tablets (100-count) for $1,032.99–$2,213.55 per order (January–December 2025); Naloxone HCL 4 mg nasal spray (2-count) for $23–$435 per order (March–April 2026); Cephalexin 500 mg capsules (500-count) for $50–$787 per order (June–August 2025); Primaquine 26.3 mg tablets for $1,082.64 (June 2025); Cyclobenzaprine 10 mg tablets for $33–$502 per order (July–December 2025); and miscellaneous antivirals, antibiotics, and pain-management medications in similar incremental quantities. Place of performance is consistently Pulaski, Tennessee, with ultimate completion dates typically one to five days after award. All orders are firm fixed price with no set-asides.

Avkare operates as a pure prime contractor with no subcontract footprint in the source data. The vendor's strategy is high-volume, low-margin transactional supply of generic pharmaceuticals and medical equipment to the federal healthcare supply chain, leveraging established relationships with DLA and VA procurement mechanisms to capture ongoing delivery-order flow under standing IDCs. The accelerating award volume from 2024 onward, combined with the modest obligated-to-potential ratio, indicates that Avkare's contracts are generating orders faster than historical patterns, likely reflecting increased federal healthcare demand or expanded vendor presence on DLA and VA supply schedules. All work is competed on an unrestricted, commercial-item basis under Federal Acquisition Regulation Part 12, indicating Avkare's posture as a full-and-open competitor without reliance on set-aside categories.